# Patent

## Title
Method for genome editing using a self-inactivating CRISPR nuclease

## Abstract

Provided are an improved genome editing system and a method that has high specificity, which are capable of obtaining stable mutation types. The system includes an expression construct including a coding sequence of a gRNA targeting at least one genomic target sequence; an expression construct including a coding sequence of a CRISPR nuclease; and an expression construct including a coding sequence for a gRNA targeting a target sequence within the coding sequence of the CRISPR nuclease. Upon introduction into the cell, the gRNA targeting the at least one genomic target sequence directs the CRISPR nuclease to the at least one genomic target sequence and results in one or more mutations in the genomic target sequence, and the gRNA targeting a target sequence within the coding sequence of the CRISPR nuclease directs the CRISPR nuclease to the target sequence within the coding sequence of the CRISPR nuclease and results in an inactivating mutation of the CRISPR nuclease.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a U.S. National Phase of International Patent Application No. PCT/CN2019/074088, filed on Jan. 31, 2019, which claims priority to Chinese Application No. 201810101165.6, filed Feb. 1, 2018. The entire contents of these applications are incorporated herein by reference in their entirety.
TECHNICAL FIELD
The invention relates to the field of genetic engineering. In particular, the present invention relates to an improved genome editing system and method that has high specificity and is capable of obtaining stable mutation types.
BACKGROUND
Genome editing technology is a genetic engineering technology based on the specific modification of the genome by specific nucleases, which plays an increasingly powerful role in agriculture and medical research. Clustered regular interspaced short palindromic repeats/CRISPR associated is the most widely used genome editing tool. Due to its high efficiency and ease of use, it has caused a worldwide revolution in the field of gene editing.
Although the CRISPR/Cas9 system has a higher efficiency of site-directed modification, the efficiency of single base mutation in the genome is still low. Komor et al. of David Liu's team from Harvard University combined CRISPR/Cas9 with cytosine deaminase to create a single-base editing system that enables efficient replacement of C to T in a site-directed manner[1]. Since then, various single-base editing systems based on deaminase have emerged. TAM (targeted AID-mediated mutagenesis) established by Changxing et al. can also achieve single-base editing by using a fusion of human cytosine deaminase to dCas9 (dCas9-AIDx)[2]. Keiji Nishida et al. fused a cytosine deaminase from Scorpion venom with Cas9 protein and UGI to achieve targeted mutations in mammalian cells with an efficiency of about 15% to 55%[3]. Scientists from Stanford University have fused cytosine deaminase to the MS2 protein, creating a CRISPR-X system that can also result in higher single-base mutation efficiency[4].
A CRISPR-based single base editing system can result in as few as one base substitution at a particular target sequence, but the length of the target sequence would not be changed. That is to say, the mutated target sequence has the same length as the target sequence that has not been mutated, while has one or more different bases. Due to the possibility of off-targeting of the CRISPR system, CRISPR nucleases may bind to and edit target sites that are slightly different from the gRNA. Therefore, with the original gRNA, the single-base editing system may still recognize the target site that has already been base-edited; and further base-editing would occur. The potential risk is that the types of mutations are not stable. Such risks also exist in other genome editing systems.
Therefore, there remains a need in the art for a new genome editing system and method that is highly specific and results in stable mutation types.
BRIEF DESCRIPTION OF THE INVENTION
In one aspect, the invention provides a genome editing system for site-directed modification of at least one genomic target sequence in the genome of a cell, comprising:
1) an expression construct comprising a coding sequence of a gRNA targeting the at least one genomic target sequence;
2) an expression construct comprising a coding sequence of a CRISPR nuclease; and
3) an expression construct comprising coding sequence for a gRNA targeting a target sequence within the coding sequence of the CRISPR nuclease,
wherein, upon introduction into the cell, said gRNA targeting the at least one genomic target sequence directs the CRISPR nuclease to said at least one genomic target sequence and results in one or more mutations in the target sequence, and the gRNA targeting a target sequence within the coding sequence of the CRISPR nuclease directs the CRISPR nuclease to said target sequence within the coding sequence of the CRISPR nuclease and results in an inactivating mutation of the CRISPR nuclease.
In another aspect, the invention provides a method of modifying at least one genomic target sequence in the genome of a cell, comprising introducing a genome editing system of the invention into the cell.
In another aspect, the invention also provides a method of producing a genetically modified cell, comprising introducing a genome editing system of the invention into a cell.
In another aspect, the invention also provides a genetically modified organism comprising the genetically modified cell produced by the method of the invention or progeny thereof.
In still another aspect, the invention also includes a kit for use in the method of the invention, wherein the kit comprises the genome editing system of the invention, and an instruction for use.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1: Genetic analysis of single-base editing mutants of rice OsWxb gene.
FIG. 2: Working principle of pSU-PBE.
FIG. 3: Expression analysis of APOBEC1-nCas9 protein.



DETAILED DESCRIPTION OF THE INVENTION
In the present invention, unless indicated otherwise, the scientific and technological terminologies used herein refer to meanings commonly understood by a person skilled in the art. Also, the terminologies and experimental procedures used herein relating to protein and nucleotide chemistry, molecular biology, cell and tissue cultivation, microbiology, immunology, all belong to terminologies and conventional methods generally used in the art. For example, the standard DNA recombination and molecular cloning technology used herein are well known to a person skilled in the art, and are described in details in the following references: Sambrook, J., Fritsch, E. F. and Maniatis, T., Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989.
In one aspect, the invention provides a genome editing system for site-directed modification of at least one genomic target sequence in the genome of a cell, comprising:
1) an expression construct comprising a coding sequence of a gRNA targeting the at least one genomic target sequence;
2) an expression construct comprising a coding sequence of a CRISPR nuclease; and
3) an expression construct comprising coding sequence for a gRNA targeting a target sequence within the coding sequence of the CRISPR nuclease, wherein, upon introduction into the cell, said gRNA targeting the at least one genomic target sequence directs the CRISPR nuclease to said at least one genomic target sequence and results in one or more mutations in the target sequence, and the gRNA targeting a target sequence within the coding sequence of the CRISPR nuclease directs the CRISPR nuclease to said target sequence within the coding sequence of the CRISPR nuclease and results in an inactivating mutation of the CRISPR nuclease. For example, said inactivating mutation is a mutation that results in an early termination of translation of the CRISPR nuclease.
The present inventors have found that a CRISPR nuclease-based genome editing system, which has been introduced into a cell and has achieved mutation(s) in the target sequence, will further edit the target sequence that has already been mutated if the genome editing system is still active in the cell (for example, the coding sequence of CRISPR nuclease or gRNA is integrated into the genome and continually expressed), and thereby change the type of mutation in the target sequence, resulting in instable mutations within the obtained cell or organism. In addition, due to the sustained activity of the genome editing system, the possibility of off-target is greatly increased.
This is especially the case for CRISPR-based single base editing systems, which can result in as few as one base substitution at a particular target sequence with the length of the target sequence unchanged (i.e., the mutated target sequence has the same length as the target sequence that has not been mutated, while has one or more different bases). Due to the possibility of off-targeting of the CRISPR system, CRISPR nucleases may bind to and edit target sites that are slightly different from the gRNA. Therefore, with the original gRNA, the single-base editing system may still recognize the target site that has already been base-edited, and further base-editing would occur. The potential risk is that the types of mutations are not stable.
However, the inventors have surprisingly discovered that by adding a gRNA targeting the coding sequence of the CRISPR nuclease in the genome editing system, the CRISPR nuclease in the cell also targets the coding sequence of itself after editing the target sequence, resulting in inactivation of the CRISPR nuclease itself (no longer expressed or expressed as a version without editing activity), which prevents further editing of the target sequence that has been mutated and thus increases the specificity of editing.
As used herein, the term “CRISPR nuclease” generally refers to a nuclease present in a naturally occurring CRISPR system, as well as modified forms thereof, variants thereof, catalytically active fragments thereof, and the like. CRISPR nuclease is capable of interacting with a crRNA and optional a tracrRNA or an artificial gRNA to recognize and/or cleave a target nucleic acid structure. The term encompasses any nuclease based on the CRISPR system that enables genome editing (including base editing) within a cell.
In some embodiments, the CRISPR nuclease includes Cas9 nucleases or variants thereof. The Cas9 nuclease may be a Cas9 nuclease from various species, such as spCas9 from S. pyogenes. 
In some embodiments, the Cas9 nuclease variant comprises a highly specific variant of Cas9 nuclease, such as the Cas9 nuclease variants eSpCas9 (1.0) (K810A/K1003A/R1060A), eSpCas9 (1.1) (K848A/K1003A/R1060A) of Feng Zhang et al., and the Cas9 nuclease variant SpCas9-HF1 (N497A/R661A/Q695A/Q926A) developed by J. Keith Joung et al.
In some embodiments, the Cas9 nuclease variant comprises a Cas9 nickase (nCas9), wherein one of the two subdomains (HNH nuclease subdomain and RuvC subdomain) of the DNA cleavage domain of Cas9 nuclease is inactivated to form a nickase.
In some embodiments, the CRISPR nuclease include Cpfl nucleases or variants thereof such as highly specific variants. The Cpf1 nuclease may be a Cpf1 nuclease from various species, such as a Cpf1 nuclease from Francisella novicida U112, Acidaminococcus sp. BV3L6, and Lachnospiraceae bacterium ND2006.
In some embodiments, the CRISPR nuclease also comprises a fusion protein of a CRISPR nuclease lacking DNA cleavage activity and a deaminase, also referred to herein as “single-base editing CRISPR nuclease”.
As used herein, “a CRISPR nuclease lacking DNA cleavage activity” includes, but is not limited to, Cas9 nickase (nCas9), nuclease-dead Cas9 nuclease (dCas9) or nuclease-dead Cpf1 nuclease (dCpf1). The nuclease-dead Cas9 nuclease (dCas9) or the nuclease-dead Cpf1 nuclease (dCpf1) completely lacks DNA cleavage activity. A number of CRISPR nucleases lacking DNA cleavage activity are known in the art.
As used herein, “deaminase” refers to an enzyme that catalyzes a deamination reaction. In some embodiments of the invention, the deaminase refers to a cytosine deaminase capable of accepting single-stranded DNA as a substrate and capable of catalyzing the deamination of cytidine or deoxycytidine to uracil or deoxyuridine, respectively. In some embodiments of the invention, the deaminase refers to adenine deaminase, which is capable of accepting single-stranded DNA as a substrate and capable of catalyzing the formation of inosine (I) from adenosine or deoxyadenosine (A). Base editing in a target DNA sequence, such as C to T conversion or A to G conversion, can be achieved by using a fusion protein of a CRISPR nuclease lacking DNA cleavage activity and a deaminase (“single-base editing CRISPR nuclease”). A variety of suitable cytosine deaminase or adenine deaminase capable of accepting single-stranded DNA as a substrate are known in the art, such as APOBEC1 deaminase, activation-induced cytidine deaminase (AID), APOBEC3G, CDA1, or for example, DNA-dependent adenine deaminase disclosed by Nicloe M. Gaudelli et al., doi: 10.1038/nature 24644, 2017.
As used herein, “gRNA” and “guide RNA” can be used interchangeably, which refers to an RNA molecule capable of forming a complex with a CRISPR nuclease and capable of targeting the complex to a target sequence due to certain complementarity to the target sequence. For example, in a Cas9-based gene editing system, a gRNA is typically composed of a crRNA and a tracrRNA molecule forming complexes through partial complement, wherein the crRNA comprises a sequence that is sufficiently complementary to a target sequence for hybridization and directs the CRISPR complex (Cas9+crRNA+tracrRNA) to specifically bind to the target sequence. However, it is known in the art that single guide RNA (sgRNA) can be designed, which comprises the characteristics of both crRNA and tracrRNA. The guide RNA of the Cpf1-mediated genome editing system is typically composed only of a mature crRNA molecule, wherein the crRNA comprises a sequence that is sufficiently identical to the target sequence to hybridize to the complement of the target sequence and direct the complex (Cpf1+crRNA) to sequence specifically bind to the target sequence. It is within the ability of those skilled in the art to design suitable gRNA sequences based on the CRISPR nucleases used and the target sequences to be edited.
In a specific embodiment of the invention, the CRISPR nuclease is APOBEC1-nCas9, which is a fusion protein of APOBEC1 deaminase and Cas9 nickase (nCas9). In some embodiments, APOBEC1-nCas9 has the amino acid sequence of SEQ ID NO:1.
In some embodiments, in order to be suitable for designing a suitable gRNA, the coding sequence of the CRISPR nuclease is modified to introduce a PAM sequence and/or a site to be mutated without altering the expression product, and if the site is mutated, the CRISPR nuclease can be inactivated. For example, one or more Cs may be included in the coding sequence of “single-base editing CRISPR nuclease” such that one or more stop codons can be formed when one or more Cs are edited to Ts by single-base editing, through which the translation of the single-base editing CRISPR nuclease is terminated, thereby preventing the continuous production of a functional single-base editing CRISPR nuclease.
For example, in some embodiments, the coding nucleotide sequence of the APOBEC1-nCas9 is shown in SEQ ID NO: 2. Accordingly, the gRNA directed against the coding sequence of the APOBEC1-nCas9 recognizes (targets) the sequence set forth in SEQ ID NO:3.
“Genome” as used herein encompasses not only chromosomal DNA present in the nucleus, but also organellar DNA present in the subcellular components (e.g., mitochondria, plastids) of the cell.
As used in the present invention, “expression construct” refers to a vector such as a recombinant vector that is suitable for expression of a nucleotide sequence of interest in a organism. “Expression” refers to the production of a functional product. For example, expression of a nucleotide sequence may refer to the transcription of a nucleotide sequence (e.g., transcription to produce mRNA or functional RNA) and/or the translation of an RNA into a precursor or mature protein. The “expression construct” of the present invention may be a linear nucleic acid fragment, a circular plasmid, a viral vector. The “expression construct” of the present invention may comprise regulatory sequences and nucleotide sequences of interest from different origins, or regulatory sequences and nucleotide sequences of interest from the same source but arranged in a manner different from that normally occurring in nature. “Regulatory sequence” and “regulatory element” are used interchangeably to refer to a nucleotide sequence that is located upstream (5 ‘non-coding sequence), middle or downstream (3’ non-coding sequence) of a coding sequence and affects the transcription, RNA processing or stability or translation of the relevant coding sequence. Regulatory sequences may include, but are not limited to, promoters, translation leaders, introns and polyadenylation recognition sequences.
Examples of promoters that can be used in the present invention include but are not limited to polymerase (pol) I, pol II or pol III promoters. Examples of pol I promoters include chicken RNA pol I promoter. Examples of pol II promoters include but are not limited to cytomegalovirus immediate early(CMV) promoter, rous sarcoma virus long terminal repeat(RSV-LTR) promoter and simian virus 40(SV40) immediate early promoter. Examples of pol III promoters include U6 and H1 promoter. Inducible promoter such as metalothionein promoter can be used. Other examples of promoters include T7 bacteriophage promoter, T3 bacteriophage promoter, β-galactosidase promoter and Sp6 bacteriophage promoter etc. When used for plants, promoters that can be used include but are not limited to cauliflower mosaic virus 35S promoter, maize Ubi-1 promoter, wheat U6 promoter, rice U3 promoter, maize U3 promoter and rice actin promoter etc.
An “expression construct” of the invention may also comprise a selectable marker for screening a transformed cell or organism, such as an antibiotic resistance marker, a herbicide resistance marker, and the like.
In the present invention, the coding sequence of the gRNA directed against the at least one genomic target sequence, the coding sequence of the CRISPR nuclease, and the coding sequence of the gRNA directed against the CRISPR nuclease may each be constructed in a separate expression construct. Alternatively, they can be constructed in a same construct in any combination. For example, if multiple genomic target sequences are to be edited, coding sequences of the gRNAs directed against these target sequences can be constructed in the same expression construct. Alternatively, for example, a coding sequence of a gRNA directed against a genomic target sequence can be constructed in the same expression construct together with a coding sequence of a gRNA directed against a CRISPR nuclease. Methods of constructing expression constructs for expression of multiple gRNAs are known in the art.
The cells which can be subjected to genome editing with the method of the present invention preferably are eukaryotic cells, include but are not limited to, mammal cells such as cells of human, mouse, rat, monkey, dog, pig, sheep, cow and cat; poultry such as chicken, duck and goose; and cells of plants including monocotyledons and dicotyledons such as rice, maize, wheat, sorghum, barley, soybean, peanut and Arabidopsis thaliana etc.
In another aspect, the invention provides a method of modifying at least one genomic target sequence in the genome of a cell, comprising introducing a genome editing system of the invention into the cell.
“Introduction” of a construct of the genome editing system of the invention into a cell means that the construct is used to transform a cell such that the construct is capable of functioning in the cell (e.g., expressing the CRISPR nuclease and/or transcribing the gRNA). As used in the present invention, “transformation” preferably means stable transformation. “Stable transformation” refers to the introduction of exogenous nucleotide sequences into the genome, resulting in the stable inheritance of foreign genes. Once stably transformed, the exogenous nucleic acid sequence is stably integrated into the genome of the organism and any of its successive generations. In some embodiments, stably transformed cells are screened by a selectable marker on the expression construct.
Methods for introducing the genome editing system of the present invention into the cell include, but are not limited to calcium phosphate transfection, protoplast fusion, electroporation, liposome transfection, microinjection, viral infection (such as a baculovirus, a vaccinia virus, an adenovirus and other viruses), particle bombardment, PEG-mediated protoplast transformation or agrobacterium-mediated transformation.
In the present invention, the target sequence in the genome of the cell may be located anywhere in the genome, for example, within a functional gene such as a protein-coding gene or, for example, may be located in a gene expression regulatory region such as a promoter region or an enhancer region, and thereby achieve the functional modification of said gene or achieve the modification of gene expression. The mutation in the target sequence in the genome of the cell can be detected by T7EI, PCR/RE or sequencing methods. The mutations may be, for example, a substitution, a deletion and/or an addition.
In another aspect, the invention also provides a method of producing a genetically modified cell comprising introducing a genome editing system of the invention into the cell.
In another aspect, the invention also provides a genetically modified organism comprising the genetically modified cell produced by the methods of the invention or progeny thereof.
“Genetically modified organism” or “genetically modified cell” means an organism or cell that contains an exogenous polynucleotide or modified gene or expression control sequence within its genome. For example, the exogenous polynucleotide is stably integrated into the genome of an organism or cell and inherited for successive generations. The exogenous polynucleotide can be integrated into the genome alone or as part of a recombinant DNA construct. The modified gene or expression control sequence is the sequence in the genome of the organism or cell that comprises single or multiple deoxynucleotide substitutions, deletions and additions. The term “exogenous” with respect to sequence means a sequence that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention.
As used herein, “organism” includes any organism, preferably a eukaryote, suitable for genome editing. The organism includes, but is not limited to mammals such as humans, mice, rats, monkeys, dogs, pigs, sheep, cows and cats; poultry such as chicken, ducks and geese; and plants including monocotyledons and dicotyledons such as rice, maize, wheat, sorghum, barley, soybean, peanuts and Arabidopsis thaliana, and the like.
In the genome editing operation of plants, constructs expressing the components for genome editing are preferably integrated into the genome to facilitate screening of transformed plants by selectable markers of the construct, so as to improve the efficiency of obtaining genome-edited plants. However, since the coding sequences of CRSPR nucleases and/or gRNAs are integrated into the plant genome, they will have sustained activity in subsequent generations, and thus there is a risk of further editing of the target sequences that have already been edited (especially in the case of single base editing), as well as higher off-target effect. Thus, the system and method of the present invention are particularly suitable for genetic modification (e.g., genome editing) of plants because the CRSPR nuclease will be inactivated upon completion of editing of the target sequence. Thus, in some preferred embodiments of the invention, the cell is a plant cell. In some preferred embodiments of the invention, the organism is a plant.
In still another aspect, the invention also includes a kit for use in the method of the invention, wherein the kit comprises the genome editing system of the invention, and an instruction for use. A kit generally includes a label indicating the intended use and/or method of use of the contents of the kit. The term label includes any written or recorded material provided in or with the kit.
EXAMPLES
The invention is further illustrated by the following examples, which are not intended to limit the invention.
Example 1. APOBEC1-nCas9 is Capable of Targeting and Further Single-Base Editing a Site where a Single Base Mutation has Occurred
The present inventors performed single-base editing on a target site in the Wxb gene of rice by designing a single sgRNA (see FIG. 1). Single base editing was performed using APOBEC1-nCas9 (SEQ ID NO: 1). The sgRNA coding sequence and the APOBEC1-nCas9 coding sequence (SEQ ID NO: 4) were integrated into the rice genome.
A mutant T0-4 was identified in T0 plants, and mutations were made at both alleles of Wxb: in one of the alleles, C at the third position of the target site was mutated to T; in the other allele, the two Cs at the third and fifth positions of the target site were mutated to T.
However, it was surprisingly found that some plants had altered mutation types during the genotyping of the mutant T1 plants. For example, one of the plants, T1-4, an allele was found in which three Cs were mutated to T, and no allele with single C-T mutation in the T0 generation was detected. This indicated that during the passage, the original sgRNA can still mediate APOBEC1-nCas9 to act on the site where base substitution has occurred.
Example 2. Imperfectly Matched sgRNA can Guide APOBEC1-nCas9 for Base Editing
In order to further prove that the edited target site can still be recognized by the original sgRNA and further edited. The inventors designed a set of sgRNAs predicted to be mismatched for verification.
A plurality of tandem Cs are present in a target sequence of the rice OsALS2 gene. The inventors designed multiple sgRNAs, each has a nucleotide that could not pair with the corresponding site of the genomic target sequence. The APOBEC1-nCas9 expression construct and the expression construct of each sgRNA were co-transformed into plants using Agrobacterium transformation, and the plants were screened by selectable markers. As a result, there is still a high mutation efficiency in the selected T0 generation. This suggests that mismatched sgRNAs can still direct APOBEC1-nCas9 for single-base editing.







TABLE 1







Efficiency of single base editing mediated


by imperfectly matched sgRNA












Summary




Target
(mutants/
mutation


No.
sequence
total plants)
efficiency





Target
CAGGTCCCCC
*
*



GCCGCATGAT




 


sgRNA-1
CAGGTCTCCC
25/41
61.0%



GCCGCATGAT




 


sgRNA-2
CAGGTCCTCC
6/9
66.7%



GCCGCATGAT




 


sgRNA-3
CAGGTCCCTC
17/28
60.7%



GCCGCATGAT









Example 3. Development of a New Single Base Editing System
First, the APOBEC1-nCas9 fusion protein was re-encoded at the DNA level (SEQ ID NO: 2): three arginine codons were set to CGA; the next arginine codon was set to AGG, creating a PAM. An sgRNA was designed to recognize the target sequence shown in FIG. 2 (SEQ ID NO: 3). A mutation of C to T in any one of the CGA codons can terminate the translation of the nCas9 protein, preventing the production of a functional fusion protein. We named this set of vectors (including the engineered APOBEC1-nCas9 vector and the corresponding sgRNA vector) as pSU-PBE. The working principle of pSU-PBE is shown in FIG. 2. The black box identifies the PAM site, and the underline identifies the target sequence on the nCas9 gene that the sgRNA is against.
Example 4. A Plant with Edited Genome Target Site and Completely Inactivated BE3 can be Obtained with the Novel Single-Base Editing System
The rice OsALS2 gene and OsNRT1.1B were edited using the pSU-PBE system plus a gene-specific sgRNA expression vector. The mutation efficiency is shown in Table 2. When the APOBEC1-nCas9 mutation is homozygous and the target site is mutated, the plants with stably inherited mutation types can be obtained in the T1 generation, with high mutation efficiency at both loci, 13.79%, 15.7%, respectively.
Plant proteins were extracted from three transgenic plants obtained with the SU systems according to the conventional operation, and western blot experiment was carried out using Anti-CRISPR-Cas9 antibody (abcam, ab204448). The internal control is Actin. As shown in FIG. 3, APOBEC1-nCas9 was not mutated in the first and third plants (first and third lanes), and the second plant was homozygous for APOBEC1-nCas9 point mutation (second lane), in which APOBEC1-nCas9 protein is not expressed.







TABLE 2







Editing efficiency of the pSU-PBE system












Mutation at
Homozygous





target site
Cas9 mutation
Total
SU mutation


Gene
(number of plants)
(number of plants)
Plants
efficiency





ALS
26 (89%)
4 (14%)
29
4/29 =






13.79%


NRT
34 (67%)
8 (16%)
51
8/51 =






15.7%









REFERENCES


    [1] Komor A C, Kim Y B, Packer M S, Zuris J A, Liu D R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 2016, 533 (7603): 420-424.
    [2] Ma Y Q, Zhang J Y, Yin W J, Zhang Z C, Song Y, Chang X. Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells. Nat Methods, 2016, 13(12): 1029-1035.
    [3] Nishida K, Arazoe T, Yachie N, Banno S, Kakimoto M, Tabata M, Mochizuki M, Miyabe A, Araki M, Hara K Y, Shimatani Z, Kondo A. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science, 2016, 353(6305): aaf8729.
    [4] Hess G T, Frésard L, Han K, Lee C H, Li A, Cimprich K A, Montgomery S B, Bassik M C. Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. Nat Methods, 2016: 13(12): 1036-1042.

## Claims

1. A genome editing system for site-directed modification of at least one genomic target sequence in the genome of a cell, comprising:
1) an expression construct comprising a coding sequence of a gRNA targeting the at least one genomic target sequence;
2) an expression construct comprising a coding sequence of a CRISPR nuclease; and
3) an expression construct comprising coding sequence for a gRNA targeting a target sequence within the coding sequence of the CRISPR nuclease,
wherein, upon introduction into the cell, said gRNA targeting the at least one genomic target sequence directs the CRISPR nuclease to said at least one genomic target sequence and results in one or more mutations in the genomic target sequence, and the gRNA targeting a target sequence within the coding sequence of the CRISPR nuclease directs the CRISPR nuclease to said target sequence within the coding sequence of the CRISPR nuclease and results in an inactivating mutation of the CRISPR nuclease,
wherein the CRISPR nuclease is a single-base editing CRISPR nuclease comprising the amino acid sequence set forth in SEQ ID NO: 1,
wherein the nucleotide sequence encoding the single-base editing CRISPR nuclease is set forth in SEQ ID NO: 2, and
wherein the target sequence within the coding sequence of the CRISPR nuclease is set forth in SEQ ID NO: 3.

2. A method of modifying at least one genomic target sequence in the genome of a cell, the method comprising introducing the genome editing system of claim 1 into the cell.

3. The method of claim 2, wherein the cell is selected from the group consisting of:
mammals selected from the group consisting of humans, mice, rats, monkeys, dogs, pigs, sheep, cows, and cats;
poultry selected from the group consisting of chicken, ducks, and geese; and
plants selected from the group consisting of rice, maize, wheat, sorghum, barley, soybean, peanuts, and Arabidopsis thaliana.

4. The method of claim 2, wherein the genome editing system is introduced into the cell by a method selected from the group consisting of calcium phosphate transfection, protoplast fusion, electroporation, liposome transfection, microinjection, viral infection, particle bombardment, PEG-mediated protoplast transformation and Agrobacterium-mediated transformation.

5. A method of producing a genetically modified cell, the method comprising introducing the genome editing system of claim 1 into a cell.

6. The method of claim 5, wherein the cell is selected from the group consisting of:
mammals selected from the group consisting of humans, mice, rats, monkeys, dogs, pigs, sheep, cows, and cats;
poultry selected from the group consisting of chicken, ducks, and geese; and

plants selected from the group consisting of rice, maize, wheat, sorghum, barley, soybean, peanuts, and Arabidopsis thaliana.

7. The method of claim 5, wherein the genome editing system is introduced into the cell by a method selected from the group consisting of calcium phosphate transfection, protoplast fusion, electroporation, liposome tra nsfection, microinjection, viral infection, particle bombardment, PEG-mediated protoplast transformation and Agrobacterium-mediated transformation.

8. A genetically modified organism comprising the genetically modified cell produced by the method of claim 5, or progeny thereof,
wherein the genetically modified organism or progeny thereof comprises the one or more mutations in the genomic target sequence.

9. A kit comprising the genome editing system of claim 1, and an instruction for use.